Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

Summary

GLACIER (Giving Long Acting CABENUVA in an Infusion center/ASA) is an interventional study examining the administration of CABENUVA (Cabotegravir long acting \[LA\] plus Rilpivirine LA) intramuscular (IM) in infusion centers/ASAs in United States. In this study, the intervention is the process of using an infusion center/ASA as the location to receive the CABENUVA IM injections. The acceptability and feasibility of the IC/ASA to deliver CABENUVA IM injections will be assessed from the perspectives of the participants, HIV care providers and IC/ASA staff. In this study, Month 1 is the Baseline visit. CABENUVA is a registered trademark of ViiV Healthcare.

Timeline

Start

2021-11-18

Primary completion

2024-01-31

Completion

2024-01-31

Publications

• Gutner CA, Harrington C, Bontempo G, Pazhamalai S, Kumar A, Rimler K, Davis K, Williams W, Merrill D, Petty L, Garris C, Sarkar S, Daniele P, Gaglio B, May K, Aboud M, Czarnogorski M. Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study. J Int Assoc Provid AIDS Care. 2026 Jan-Dec;25:23259582261439585. doi: 10.1177/23259582261439585. Epub 2026 May 12.

Drugs

Indications